Breaking News

Coherus Biosciences Names Commercial Strategy SVP

April 28, 2014

Fleming brings more than 25 years of biopharma experience

Michael A. Fleming has been appointed senior vice president of Commercial Strategy at Coherus Biosciences.
 
Mr. Fleming has more than 25 years of experience in the biopharma industry, including senior leadership and executive management roles with Elan Corp., Nuvelo, Inc., Genentech, GlaxoSmithKline, SmithKline Beecham, and inVentiv Health. He has been instrumental in the launch, commercialization, and business development of numerous products in various therapeutic areas including HIV, infectious diseases, diabetes, CNS, multiple sclerosis, cardiovascular, and oncology.
 
"Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, president and chief executive officer of Coherus. "Our pipeline is now sufficiently advanced to begin evaluating our strategic options for commercialization. Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance. He will play a key role in defining strategies that effectively maximize the commercial potential of our products."
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision